文献速递腹部介入CTMRPET

经皮影像引导肝肿瘤冷冻消融:单中心中长期结局经验

Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes.
PubMed 文献 · AJR Am J Roentgenol · 2017-09-27

单中心回顾性分析1998至2014年186例患者299个肝肿瘤接受CT、MRI或PET/CT引导经皮冷冻消融的中长期结局,技术成功率94.6%,3个月技术有效率89.5%,肿瘤小于4 cm者有效率93.4%高于较大肿瘤的60.0%,局部肿瘤进展率23.3%,33.8%的操作发生不良事件,10.6%为3-5级。

要点

  • 肿瘤小于4 cm者3个月技术有效率93.4%(213/228),显著高于4 cm及以上者的60.0%(18/30)(p < 0.0001)。
  • 局部肿瘤进展率23.3%(60/258),4 cm及以上肿瘤为63.3%(19/30),高于小于4 cm肿瘤的18.0%(41/228)(p < 0.0001)。
  • 33.8%(80/236)的操作发生不良事件,10.6%(25/236)为3-5级;4 cm及以上肿瘤3级及以上不良事件为19.5%(8/41),高于小于4 cm肿瘤的8.7%(17/195)(p = 0.04)。

核心结论

  • 影像引导经皮肝肿瘤冷冻消融有效,但小于4 cm的肿瘤更可能被成功治疗且不发生不良事件。

研究设计与样本

  • 单中心经验,1998至2014年间186例患者(95例女性;平均年龄60.9岁,范围29-88岁)299个肝肿瘤(243个转移瘤、56个原发瘤;平均直径2.5 cm,中位直径2.2 cm,范围0.3-7.8 cm)在236次操作中接受冷冻消融,引导方式为CT(n = 126)、MRI(n = 100)或PET/CT(n = 10)。

关键影像表现/征象

  • 计算了技术成功、3个月技术有效率、局部肿瘤进展(平均随访2.5年,范围2个月至14.6年)及不良事件率,原文未描述具体影像征象。

诊断标准与关键数值

  • 技术成功率为94.6%(279/295);3个月技术有效率为89.5%(231/258),肿瘤小于4 cm者为93.4%(213/228),大于等于4 cm者为60.0%(18/30)(p < 0.0001)。

临床应用与阅片要点

  • 影像引导经皮肝肿瘤冷冻消融有效;肿瘤小于4 cm者更可能被成功治疗且不发生不良事件,肿瘤大于等于4 cm者局部肿瘤进展和3级及以上不良事件更常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this article is to report our intermediate to long-term outcomes with image-guided percutaneous hepatic tumor cryoablation and to evaluate its technical success, technique efficacy, local tumor progression, and adverse event rate.

MATERIALS AND METHODS: Between 1998 and 2014, 299 hepatic tumors (243 metastases and 56 primary tumors; mean diameter, 2.5 cm; median diameter, 2.2 cm; range, 0.3-7.8 cm) in 186 patients (95 women; mean age, 60.9 years; range, 29-88 years) underwent cryoablation during 236 procedures using CT (n = 126), MRI (n = 100), or PET/CT (n = 10) guidance. Technical success, technique efficacy at 3 months, local tumor progression (mean follow-up, 2.5 years; range, 2 months to 14.6 years), and adverse event rates were calculated.

RESULTS: The technical success rate was 94.6% (279/295). The technique efficacy rate was 89.5% (231/258) and was greater for tumors smaller than 4 cm (93.4%; 213/228) than for larger tumors (60.0%; 18/30) (p < 0.0001). Local tumor progression occurred in 23.3% (60/258) of tumors and was significantly more common after the treatment of tumors 4 cm or larger (63.3%; 19/30) compared with smaller tumors (18.0%; 41/228) (p < 0.0001). Adverse events followed 33.8% (80/236) of procedures and were grade 3-5 in 10.6% (25/236) of cases. Grade 3 or greater adverse events more commonly followed the treatment of larger tumors (19.5%; 8/41) compared with smaller tumors (8.7%; 17/195) (p = 0.04).

CONCLUSION: Image-guided percutaneous cryoablation of hepatic tumors is efficacious; however, tumors smaller than 4 cm are more likely to be treated successfully and without an adverse event.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Glazer DI, Tatli S, Shyn PB, et al. Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes. AJR Am J Roentgenol. 2017. PMID: 28952807. doi:10.2214/AJR.16.17582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。